Coping with a worldwide shortage, some individuals prescribed ADHD medication in New Zealand are facing difficulties securing consistent supplies.
Photo: 123RF
A concerning global shortage of ADHD medications is affecting New Zealand, prompting experts to urge individuals with ADHD against sharing their prescriptions.
Darrin Bull,spokesperson for ADHD New Zealand,highlights the challenging situation many are facing. “some people are having to make difficult decisions, like rationing their medication to stretch their prescription further,” he explains.
Driving this crisis is a global shortage of methylphenidate, the active ingredient in medications like Ritalin, Concerta, and Teva. This shortage has persisted for over a year, causing significant anxiety among those who rely on these medications.
ADHD is estimated to affect over 250,000 New Zealanders. While prescription rates have risen tenfold between 2006 and 2022, only about 20 percent of those with ADHD are currently receiving treatment.
Medsafe, New Zealand’s medicine regulator, strongly cautions against acquiring or sharing prescription medications online or through social media platforms, emphasizing the illegality of these actions.
Alternatives to medication, such as working with an ADHD coach, are also available. ADHD new Zealand provides facts on a range of non-medical approaches, including support groups, acupuncture, therapy, and occupational therapy.
The current shortage is expected to continue until mid-2025.
New Treatment Option Now Subsidized
There’s a glimmer of hope on the horizon as Pharmac, New Zealand’s drug-buying agency, has extended funding to include lisdexamfetamine, sold under the brand name Vyvanse.
Even though Vyvanse has been available privately in new Zealand as 2023, funding as a subsidized option began on December 1st. This move is anticipated to alleviate some of the pressure on the supply of other ADHD medications.
Pharmac projects that over 6,000 individuals with ADHD will benefit from subsidized lisdexamfetamine in its first year of funding,with this number expected to rise to approximately 13,000 after five years.
How can individuals with ADHD manage their condition during the current medication scarcity?
Interview with Darrin Bull: Understanding the ADHD Medication shortage in New Zealand
Time.news Editor: Thank you for joining us today, Darrin. As the spokesperson for ADHD new Zealand, can you explain the current challenges individuals with ADHD face regarding medication access in New Zealand?
Darrin Bull: Thank you for having me. The situation is indeed concerning. We’re experiencing a critically important global shortage of ADHD medications, especially those containing methylphenidate, wich is the active ingredient in well-known medications like Ritalin and Concerta. Many individuals prescribed these medications are struggling to secure consistent supplies, leading some to make tough choices, such as rationing their medication to make it last longer.
Time.news Editor: That sounds quite distressing. What factors have contributed to this ongoing shortage?
Darrin Bull: The shortage has been persistent for over a year and is primarily due to manufacturing issues with the pharmaceutical companies that produce methylphenidate. As ADHD is estimated to affect over 250,000 New Zealanders, the demand for these medications has surged—prescription rates have risen tenfold between 2006 and 2022. Unluckily, only about 20 percent of those affected are currently receiving treatment, illustrating the magnitude of the issue.
Time.news Editor: With the rising demand and diminished supply, are there any safety concerns related to obtaining these medications through unofficial channels?
Darrin Bull: Absolutely. Medsafe, New zealand’s medicine regulator, has strongly warned against acquiring or sharing prescription medications online or through social media. Not only is this illegal, but it also places individuals at significant risk, as these sources may provide counterfeit or unsafe products. we urge individuals to prioritize their safety and adhere to guidelines set by healthcare authorities.
Time.news Editor: What alternatives do individuals with ADHD have while facing this shortage?
Darrin bull: There are non-medical approaches that can be beneficial, such as working with an ADHD coach, participating in support groups, and considering therapy, acupuncture, or occupational therapy. ADHD New Zealand provides resources on these alternatives. It’s essential for individuals to explore these options, especially in the current landscape.
Time.news Editor: The article mentions a new treatment option,lisdexamfetamine,which is now subsidized in New Zealand. How will this change the outlook for those struggling with ADHD?
Darrin Bull: Yes, there is a glimmer of hope! Pharmac, New Zealand’s drug-buying agency, has begun funding lisdexamfetamine, sold under the brand name Vyvanse, as of December 1st. This move is expected to alleviate some pressure on the supply of other ADHD medications. Initially, over 6,000 individuals are projected to benefit from this subsidized option in the frist year, which is significant, especially considering the urgency of the situation.
Time.news Editor: That’s encouraging news,indeed. what practical advice would you offer to readers affected by these shortages?
Darrin Bull: my primary advice is to remain in close contact with your healthcare provider.Open dialogue can definitely help you explore option treatments and support options tailored to your specific needs. Additionally, avoid sharing prescriptions with others, as this can lead to complications and is illegal. We want everyone to stay safe and receive the care they need.
Time.news Editor: Thank you,Darrin,for shedding light on this critical issue. Your insights are invaluable for many navigating these challenges.
Darrin Bull: Thank you for having me! It’s essential that we all work together to address ADHD care and support.